Dr. Reddy's Laboratories faces legal action in the United States

Dr. Reddy's Laboratories, Inc., a wholly-owned step-down subsidiary of Dr. Reddy's Laboratories Limited, has found itself among several pharmaceutical companies named as defendants in a complaint filed on October 6, 2023. The complaint was lodged in the United States District Court for the Northern District of California by Mayo Clinic and Lifepoint Corporate Services.

The complaint alleges violations of federal and state antitrust laws, as well as other state laws, asserting that the defendants engaged in improper competition restraint and maintained a shared monopoly in the sale of brand and generic Revlimid through settlements of patent litigation. According to the complaint, these agreements resulted in an improper delay of generic entry until 2022 and then limited generic competition through 2026.

In response to these allegations, Dr. Reddy's Laboratories has stated that it believes the claims lack merit and has vowed to vigorously defend itself against the litigation.